Skip to main content

Market Overview

Orchard Therapeutics: Q1 Earnings Insights

Share:

Shares of Orchard Therapeutics (NASDAQ:ORTX) fell 1.5% after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 45.71% over the past year to ($0.51), which were in line with the estimate of ($0.51).

Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $490,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 07, 2020

Time: 11:01 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/h3uyhwmi

Recent Stock Performance

Company's 52-week high was at $20.50

52-week low: $5.17

Price action over last quarter: down 10.36%

Company Profile

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

 

Related Articles (ORTX)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com